Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 536.83M P/E - EPS this Y 19.80% Ern Qtrly Grth -
Income -28.3M Forward P/E -28.69 EPS next Y -23.70% 50D Avg Chg -28.00%
Sales 170k PEG - EPS past 5Y - 200D Avg Chg -13.00%
Dividend N/A Price/Book 184.46 EPS next 5Y - 52W High Chg -50.00%
Recommedations 2.00 Quick Ratio 3.54 Shares Outstanding 26.87M 52W Low Chg 286.00%
Insider Own 22.31% ROA -90.37% Shares Float 19.99M Beta -
Inst Own 21.80% ROE - Shares Shorted/Prior 2.03M/1.85M Price 20.66
Gross Margin 100.00% Profit Margin - Avg. Volume 46,503 Target Price 26.00
Oper. Margin -14,214.71% Earnings Date - Volume 24,467 Change 0.78%
About Genelux Corporation

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Genelux Corporation News
04/26/24 Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
04/23/24 Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
04/05/24 After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)
04/04/24 All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy
04/01/24 Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
12/15/23 Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX)
11/27/23 Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
11/17/23 Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%
11/14/23 Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
10/20/23 12 Best Performing Biotech Stocks in 2023
09/19/23 Director John Thomas Sells 6667 Shares of Genelux Corp (GNLX)
09/15/23 Director John Smither Sells 900 Shares of Genelux Corp (GNLX)
09/14/23 10% Owner Aladar Szalay Sells 52,616 Shares of Genelux Corp (GNLX)
09/14/23 Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/07/23 Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
08/31/23 Genelux (NASDAQ:GNLX) Is In A Good Position To Deliver On Growth Plans
08/28/23 Genelux Corporation Announces New Chief Financial Officer
08/14/23 Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
03:00 PM Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023
12:08 AM 10 Recent IPOs in 2023 to Consider
GNLX Chatroom

User Image insiderbuyingselling Posted - 04/24/24

$GNLX new insider selling: 44395 shares. http://insiderbuyingselling.com/?t=GNLX

User Image Stocksrunner Posted - 04/23/24

$GNLX 📈 Power Hour Market Update: Key Technical Indicators Genelux Corporation down -45.44% in 4 weeks, showing signs of overselling. Could a turnaround be on the horizon? https://stocksrunner.com/symbol/GNLX

User Image SharkE24 Posted - 04/22/24

$GNLX run, do not walk, to the nearest exit.

User Image SharkE24 Posted - 04/22/24

$GNLX a proper pump and total dump.

User Image bingbongd Posted - 04/22/24

$GNLX when the Directors are selling under 4$, you might wanna GTFO too

User Image Sixth_Sense Posted - 04/22/24

$GNLX nope this one’s a dud

User Image Sixth_Sense Posted - 04/22/24

$GNLX in here for a swing. Let’s see if we get some capitulation. Severely undervalued

User Image Buytheripsellthedipest Posted - 04/21/24

My idiot scheme to be confirmed tomorrow with pre market and with futures not in panic mode (valid just 4 me and maybe not even) $IMNN .... entrance at 1.20 .. if so trying 1.80 $GNLX.... entrance 3.87... if so trying trying 5.20 (many doubts on it mostly 4 the latest insider selling) Aggressive blackberries: $RENT ... entrance 11.2 ....if so, crossing fingers until 20 $CSRL ... any entrance good if largely above MA20... exit in the around or just below 1.50 Ciao 👋

User Image insiderbuyingselling Posted - 04/18/24

$GNLX new insider selling: 71420 shares. http://insiderbuyingselling.com/?t=GNLX

User Image 05ford Posted - 04/15/24

$GNLX so what is everyone’s guess for the bottom on this? Bought in at $6, added at $5 & again at $4. I believe the ipo price was around $6, then the big run-up and back to earth. That $300mil securities shelf seemed to enhance the sell-off. Hopefully levels off soon…

User Image Stocksrunner Posted - 04/05/24

$GNLX Oversold, Potential for Trend Reversal Ahead Genelux Corporation has been mired in a downtrend lately, plunging 26.21% over the past four weeks. However, this steep decline may be setting the stage for a potential trend reversal. https://stocksrunner.com/symbol/GNLX

User Image stockregion Posted - 04/04/24

Genelux Corporation: A Speculative Buy Worth Considering? In the volatile world of biotech investments, pinpointing potential high-reward stocks can be akin to finding a needle in a haystack. Yet, the recent analysis by Benchmark on Genelux Corporation (Ticker Symbol: GNLX) has caught the attention of many in the industry. With a reiterated speculative buy rating and a staggering price target of $30—nearly six times its current trading price of $5.11—Genelux emerges as a compelling narrative in the sector. $GNLX https://stockregion.app/p/cancer-therapy-company-receives-buy

User Image DonCorleone77 Posted - 1 month ago

$GNLX Genelux reports Q4 EPS (25c), consensus (19c) "Last year was highlighted by the ongoing advancement of our clinical pipeline focused on platinum re-sensitization, including our pivotal Phase 3 trial in platinum resistant/refractory ovarian cancer and development of our two systemic administration trials in lung cancer," said Thomas Zindrick, President, Chairman and CEO of Genelux. "Looking ahead, we anticipate the culmination of these trials not only holds promise for enhancing the therapeutic landscape but also underscores our dedication to advancing scientific understanding and offering new hope to patients grappling with the complexities of various cancers."

User Image Stock_Titan Posted - 1 month ago

$GNLX Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update https://www.stocktitan.net/news/GNLX/genelux-corporation-reports-fourth-quarter-and-full-year-2023-itqkvyajflkl.html

User Image Jonathanthewiz Posted - 03/21/24

$GNLX this is looking good for a swing trade imo good time to start loading up

User Image WeighProtein Posted - 03/18/24

$GNLX in for a swing

User Image ItTakesItAll Posted - 02/27/24

$GNLX 10% already 🤔

User Image ItTakesItAll Posted - 02/26/24

$GNLX adding. Long Term.

User Image MoneyMakinManhattan Posted - 02/06/24

$GNLX what a fucking steal at these levels! Load up and hold until summer.

User Image DonCorleone77 Posted - 2 months ago

$GNLX Genelux files $300M mixed securities shelf

User Image MoneyMakinManhattan Posted - 01/29/24

$GNLX love love these levels..

User Image MoneyMakinManhattan Posted - 01/06/24

$GNLX looking to add more, but not at these levels. 😩

User Image ChartMill Posted - 12/23/23

$GNLX was analyzed by 10 analysts. The buy consensus is at 82%. So analysts seem to be very confident about $GNLX. https://www.chartmill.com/stock/quote/GNLX/analyst-ratings?utm_source=ANALYST&utm_medium=stocktwits&utm_campaign=ANALYST&utm_content=GNLX

User Image tickeron Posted - 12/21/23

If you are an active trader, pay attention! $GNLX enters an Uptrend as Momentum Indicator exceeded the 0 level on December 19, 2023. View odds for this and other indicators: https://srnk.us/go/4947215

User Image UltraAlgo Posted - 12/20/23

$GNLX Rating downgraded to Sell from 5 signals, 15-min chart. 💰 See signals at UltraAlgo https://i.redd.it/7rd2jli88c7c1.png

User Image cctranscripts Posted - 12/18/23

VP of GENELUX CORP just disposed of 32,535 shares https://www.conferencecalltranscripts.org/summary/?id=12801148 $GNLX

User Image risenhoover Posted - 12/18/23

Insider Tony Yu reports selling 32,535 shares of $GNLX for a total cost of $428,179.82 https://fintel.io/n/us/gnlx/yu-tony?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=insider

User Image tradingtwenty Posted - 12/15/23

Top 5 after-hours stocks that have trended in the past 24 hours: $ICCT 37.06% 🔥 $ARQT 27.05% $IGMS 9.70% $GNLX 8.02% $BNZI 7.70% Link: https://tradingtwenty.com/dashboard/trending/past

User Image MarketBeatInsiderTrades Posted - 12/15/23

Genelux Director John Thomas Sells $120,420.00 in $GNLX www.marketbeat.com/stocks/NASDAQ/GNLX/insider-trades/

User Image cctranscripts Posted - 12/14/23

GENELUX CORP director just disposed of 9,000 shares https://www.conferencecalltranscripts.org/summary/?id=12794457 $GNLX

Analyst Ratings
Benchmark Speculative Buy Apr 3, 24
HC Wainwright & Co. Buy Apr 2, 24
HC Wainwright & Co. Buy Nov 27, 23
Benchmark Speculative Buy Nov 24, 23
Maxim Group Buy Sep 12, 23
Benchmark Speculative Buy Jun 9, 23
Brookline Capital Hold May 18, 23
Benchmark Speculative Buy Feb 15, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Tyree James L Director Director Dec 13 Sell 13.32 9,000 119,880 3,460 12/14/23
Thomas John Director Director Dec 13 Sell 13.58 9,000 122,220 463,460 12/14/23
Yu Yong VP, Clinical Trial O.. VP, Clinical Trial Operations Dec 07 Sell 11.8477 36,800 435,995 32,535 12/08/23
Szalay Aladar 10% Owner 10% Owner Oct 25 Sell 19.3965 5,704 110,638 1,371,545 10/26/23
Szalay Aladar 10% Owner 10% Owner Oct 23 Sell 19.9725 49,987 998,365 1,377,249 10/25/23
Yu Yong VP, Clinical Trial O.. VP, Clinical Trial Operations Oct 24 Sell 19.11 5,200 99,372 106,135 10/25/23
Yu Yong VP, Clinical Trial O.. VP, Clinical Trial Operations Oct 24 Option 6 5,200 31,200 111,335 10/25/23
Thomas John Director Director Oct 16 Sell 20.9 3,333 69,660 472,460 10/16/23
Szalay Aladar 10% Owner 10% Owner Oct 05 Sell 25.18 14,251 358,840 1,427,236 10/10/23
Szalay Aladar 10% Owner 10% Owner Oct 03 Sell 25.4885 75,690 1,929,225 1,441,487 10/04/23
Szalay Aladar 10% Owner 10% Owner Sep 27 Sell 24.3 13,546 329,168 1,517,177 09/29/23
Szalay Aladar 10% Owner 10% Owner Sep 25 Sell 25.14 42,263 1,062,492 1,530,723 09/27/23
Szalay Aladar 10% Owner 10% Owner Sep 21 Sell 27.84 16,591 461,893 1,572,986 09/25/23
Szalay Aladar 10% Owner 10% Owner Sep 18 Sell 25.19 62,459 1,573,342 09/20/23
Yu Yong VP, Clinical Trial O.. VP, Clinical Trial Operations Sep 15 Sell 21.92 10,400 227,968 106,135 09/18/23
Yu Yong VP, Clinical Trial O.. VP, Clinical Trial Operations Sep 15 Option 6 10,400 62,400 116,535 09/18/23
Thomas John Director Director Sep 15 Sell 23.01 6,667 153,408 475,793 09/18/23
Yu Yong VP, Clinical Trial O.. VP, Clinical Trial Operations Sep 13 Sell 21.1385 29,800 629,927 106,135 09/15/23
Smither John W Director Director Sep 13 Sell 20.78 900 18,702 6,920 09/14/23
Szalay Aladar 10% Owner 10% Owner Sep 11 Sell 22.05 52,616 1,160,183 79,600 09/13/23
Szalay Aladar 10% Owner 10% Owner Sep 07 Sell 23.98 37,277 893,902 132,216 09/11/23
Yu Yong VP, Clinical Trial O.. VP, Clinical Trial Operations Aug 30 Sell 24.70 19,800 489,060 135,935 08/30/23
Yu Yong VP, Clinical Trial O.. VP, Clinical Trial Operations Aug 18 Sell 23.73 3,265 77,478 155,735 08/22/23
Zindrick Thomas President and CEO President and CEO Aug 18 Sell 23.73 8,349 198,122 14,651 08/22/23